Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Kinetics of polythiazide.

D C Hobbs, T M Twomey

Clinical Pharmacology and Therapeutics

|February 1, 1978

Summary

This summary is machine-generated.

A new assay accurately measures polythiazide plasma levels. This high-potency diuretic has a long elimination half-life of 25.7 hours, consistent with its extended action.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Ampiroxicam, an anti-inflammatory agent which is a prodrug of piroxicam.

Agents and actions·1993

Same author

Effects of doxazosin on atherosclerosis in cholesterol-fed rabbits.

Atherosclerosis·1993

Same author

Disposition of ampiroxicam, a prodrug of piroxicam, in man.

Xenobiotica; the fate of foreign compounds in biological systems·1990

Same author

Liquid chromatographic analysis of doxazosin in human serum with manual and robotic sample preparation.

Journal of chromatographic science·1988

Same author

Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex, and adverse effects.

The American journal of medicine·1986

Same author

Pharmacokinetics of piroxicam in man.

European journal of rheumatology and inflammation·1983

Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026

Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026

Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026

Same journal

Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

Clinical pharmacology and therapeutics·2026

Same journal

Ruxolitinib Pharmacokinetics and Exposure-Toxicity Relationship in Hematologic Malignancies and Immune-Mediated Diseases: A Prospective Observational Study.

Clinical pharmacology and therapeutics·2026

Same journal

Repurposing Registries: Completeness of Real-World Data for Regulatory and HTA Purposes in Three Cancer-Focused Registries.

Clinical pharmacology and therapeutics·2026

See all related articles

Area of Science:

Pharmacology
Analytical Chemistry

Background:

Polythiazide is a potent diuretic requiring sensitive measurement methods.
Understanding its pharmacokinetics is crucial for clinical application.

Purpose of the Study:

To develop a sensitive assay for quantifying polythiazide in human plasma.
To determine the pharmacokinetic profile of polythiazide in healthy subjects.

Main Methods:

Assay development using acid hydrolysis and electron-capture gas chromatography.
Plasma concentration analysis in human subjects after a 1-mg oral dose.

Main Results:

Achieved assay sensitivity down to 0.2 ng/ml.
Mean absorption and elimination half-lives were 1.2 and 25.7 hours, respectively.

Related Experiment Videos

Approximately 25% of the drug was excreted unchanged in urine.

Conclusions:

The developed assay is suitable for measuring therapeutic polythiazide concentrations.
The long elimination half-life supports polythiazide's extended duration of action.
Pharmacokinetic data provide insights into polythiazide's disposition in humans.